Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
Among patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who were receiving maximum tolerated doses of lipid-lowering therapy and were at high risk for cardiovascular events, obicetrapib reduced LDL cholesterol levels by 29.9%. (Funded by NewAmsterdam Pharma; BROADWAY ClinicalTrials.gov number, NCT05142722.).
Authors
- Kausik Kumar Ray (ORCID: https://orcid.org/0000-0003-0508-0954)
- Annie Neild
- Douglas Kling
- Roxana Mehran (ORCID: https://orcid.org/0000-0002-5546-262X)
- Violeta Balinskaite (ORCID: https://orcid.org/0000-0003-3195-8820)
- Julie Butters
- Mariko Harada‐Shiba (ORCID: https://orcid.org/0000-0002-7600-2059)
- Steven E. Nissen (ORCID: https://orcid.org/0000-0002-7231-6464)
- Maciej Banach (ORCID: https://orcid.org/0000-0001-6690-6874)
- Ann Marie Návar (ORCID: https://orcid.org/0000-0002-6197-9860)
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Stephen James Nicholls (ORCID: https://orcid.org/0000-0002-9668-4368)
- Adam J. Nelson (ORCID: https://orcid.org/0000-0003-0990-2548)
- Ulrich Laufs (ORCID: https://orcid.org/0000-0003-2620-9323)
- Danielle Curcio (ORCID: https://orcid.org/0009-0005-1672-0760)
- Michael Szarek (ORCID: https://orcid.org/0000-0002-0046-0264)
- John J.P. Kastelein (ORCID: https://orcid.org/0000-0003-2018-4532)
- Marc Ditmarsch (ORCID: https://orcid.org/0000-0002-2970-1893)
- Yong Huo (ORCID: https://orcid.org/0000-0002-5407-8773)
- Alberico L. Catapano (ORCID: https://orcid.org/0000-0002-7593-2094)
- Andrew Hsieh (ORCID: https://orcid.org/0000-0001-6671-6878)
- Michael H. Davidson (ORCID: https://orcid.org/0000-0001-9342-1274)
- Brian A. Ference
Institutions
- Medpace (United States) (US)
- Cleveland Clinic (US)
- State University of New York (US)
- Baylor College of Medicine (US)
- SUNY Downstate Health Sciences University (US)
- University of Milan (IT)
- Peking University (CN)
- University of Cambridge (GB)
- Southwestern Medical Center (US)
- Mount Sinai Hospital (US)
- Medical University of Lodz (PL)
- Peking University First Hospital (CN)
- Mylan (Switzerland) (CH)
- Southwestern Medical Center (US)
- Imperial College London (GB)
- University of Colorado Anschutz Medical Campus (US)
- Monash University (AU)
- The University of Texas Southwestern Medical Center (US)
- University of Amsterdam (NL)
- Osaka University of Pharmaceutical Sciences (JP)
- Leipzig University (DE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1056/nejmoa2415820
- Citations
- 63
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 126.41